rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
1989-12-21
|
pubmed:abstractText |
The results of this preliminary clinical trial confirm the thrombolytic effect of defibrotide demonstrated in preclinical models; demonstrate the positive influence of the product on the natural history of early AMI; suggest that the optimal dosage range should include not less than 1.6 gm of defibrotide during the first hour of treatment; and justify further commitment in the study of defibrotide also beyond the scope of treating AMI.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0094-6176
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
464-9
|
pubmed:dateRevised |
2006-3-7
|
pubmed:meshHeading |
pubmed-meshheading:2814516-Dose-Response Relationship, Drug,
pubmed-meshheading:2814516-Drug Administration Schedule,
pubmed-meshheading:2814516-Drug Evaluation,
pubmed-meshheading:2814516-Drug Therapy, Combination,
pubmed-meshheading:2814516-Fibrinolytic Agents,
pubmed-meshheading:2814516-Humans,
pubmed-meshheading:2814516-Myocardial Infarction,
pubmed-meshheading:2814516-Myocardial Reperfusion,
pubmed-meshheading:2814516-Necrosis,
pubmed-meshheading:2814516-Polydeoxyribonucleotides
|
pubmed:year |
1989
|
pubmed:articleTitle |
Use of defibrotide in the treatment of acute myocardial infarction.
|
pubmed:affiliation |
Coronary Care Unit, Echocardiography Service, S. Camillo Hospital, Rome, Italy.
|
pubmed:publicationType |
Journal Article
|